Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Summit Therapeu ADR
(NQ:
SMMT
)
21.21
-0.36 (-1.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeu ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
10 Health Care Stocks With Whale Alerts In Today's Session
October 16, 2024
Via
Benzinga
Up 700% This Year, Is It Too Late to Invest in This Stock?
October 15, 2024
The shares have experienced a pullback in the past couple of weeks.
Via
The Motley Fool
Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics
October 13, 2024
It's hard to go wrong with either company, but one is more appealing.
Via
The Motley Fool
3 Things You Need to Know If You Buy Summit Therapeutics Stock Today
October 12, 2024
It's easier to invest confidently when you know both the pros and the cons in full.
Via
The Motley Fool
(SMMT) - Analyzing Summit Therapeutics's Short Interest
October 10, 2024
Via
Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
October 07, 2024
The investment bank analysts who follow these stocks think they can soar even further, with some caveats.
Via
The Motley Fool
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
October 06, 2024
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop.
Via
Benzinga
Is Summit Therapeutics a Millionaire Maker?
October 05, 2024
This company's promising cancer drug could challenge Merck's $25 billion crown jewel.
Via
The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Could Summit Therapeutics Become the Next Merck?
October 04, 2024
Recent developments are forcing comparisons between these two drugmakers.
Via
The Motley Fool
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
October 04, 2024
Via
Benzinga
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
October 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Where Will Summit Therapeutics Be in 3 Years?
October 03, 2024
There's a lot riding on how its collaborator's studies end up performing.
Via
The Motley Fool
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
October 02, 2024
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar.
Via
Benzinga
Has Summit Therapeutics Stock Already Peaked?
October 02, 2024
Summit Therapeutics stock is up a remarkable 700% this year.
Via
The Motley Fool
Is Summit Therapeutics Stock a Buy?
September 30, 2024
Its alliance with a successful foreign biotech could be decisive for the stock.
Via
The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
September 29, 2024
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio?
Via
Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
September 29, 2024
These two growth stocks have plenty of room to run.
Via
The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
September 28, 2024
One of them is performing much better than the other this year.
Via
The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
September 25, 2024
These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
Via
The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
September 22, 2024
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90%
Via
Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
September 22, 2024
How long will the momentum last?
Via
The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Via
AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
September 19, 2024
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge.
Via
News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
September 19, 2024
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study.
Via
The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days.
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
September 16, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.